Who
Arun Swarup Menawat
Director
Company insider
Files Form 4 as: Chairman, Firefly Neuroscience; Director, Stereotaxis; CEO, Profound Medical.
In numbers
- Trades disclosed
- 37
- Buys
- 2
- Sells
- 0
- Bought
- $100K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 29 Sep 2016
- Last trade
- 25 Sep 2026
- Last filed
- 29 Sep 2026
Companies traded
Activity over time
1 May 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Sep 2026filed 29 Sep 2026 | AIFF Firefly Neuroscienceoption or derivative · Software | SEC FORM 4 Code A | —126,050 at $0.00 | filing |
| 25 Sep 2026filed 29 Sep 2026 | AIFF Firefly Neuroscienceoption or derivative · Software | SEC FORM 4 Code A | —126,050 at $0.00 | filing |
| 1 Jul 2026filed 1 Jul 2026 | STXS StereotaxisMedical Devices | SEC FORM 4 Code A | —43,103 at $0.00 | filing |
| 1 Jul 2026filed 1 Jul 2026 | STXS StereotaxisMedical Devices | SEC FORM 4 Code A | —43,103 at $0.00 | filing |
| 2 Jan 2026filed 2 Jan 2026 | STXS StereotaxisMedical Devices | SEC FORM 4 Code A | —46,948 at $0.00 | filing |
| 2 Jan 2026filed 2 Jan 2026 | STXS StereotaxisMedical Devices | SEC FORM 4 Code A | —46,948 at $0.00 | filing |
| 28 Oct 2025filed 30 Oct 2025 | AIFF Firefly Neuroscienceoption or derivative · Software | SEC FORM 4 Code A | —73,892 at $0.00 | filing |
| 1 Jul 2025filed 3 Jul 2025 | STXS StereotaxisMedical Devices | SEC FORM 4 Code A | —43,668 at $0.00 | filing |
| 19 May 2025filed 20 May 2025 | AIFF Firefly Neuroscienceoption or derivative · Software | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 16 May 2025filed 20 May 2025 | PROF Profound MedicalMedical Devices | SEC FORM 4 Bought | $57K12,027 at $4.73 | filing |
| 15 May 2025filed 20 May 2025 | PROF Profound MedicalMedical Devices | SEC FORM 4 Bought | $43K10,003 at $4.33 | filing |
| 10 Mar 2025filed 12 Mar 2025 | AIFF Firefly Neuroscienceoption or derivative · Software | SEC FORM 4 Code A | —16,667 at $0.00 | filing |
| 2 Jan 2025filed 2 Jan 2025 | STXS StereotaxisMedical Devices | SEC FORM 4 Code A | —56,497 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | STXS StereotaxisMedical Devices | SEC FORM 4 Code A | —53,475 at $0.00 | filing |
| 2 Jan 2024filed 2 Jan 2024 | STXS StereotaxisMedical Devices | SEC FORM 4 Code A | —64,935 at $0.00 | filing |
| 3 Jul 2023filed 3 Jul 2023 | STXS StereotaxisMedical Devices | SEC FORM 4 Code A | —47,619 at $0.00 | filing |
| 3 Jan 2023filed 3 Jan 2023 | STXS StereotaxisMedical Devices | SEC FORM 4 Code A | —54,054 at $0.00 | filing |
| 1 Jul 2022filed 1 Jul 2022 | STXS StereotaxisMedical Devices | SEC FORM 4 Code A | —15,527 at $0.00 | filing |
| 4 Jan 2022filed 4 Jan 2022 | STXS StereotaxisMedical Devices | SEC FORM 4 Code A | —10,449 at $0.00 | filing |
| 1 Jul 2021filed 6 Jul 2021 | STXS StereotaxisMedical Devices | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
News
Profound Medical (NASDAQ:PROF) Upgraded to Hold at Wall Street ZenPROF · themarketsdaily.com · 11 Oct 2026Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate CarePROF · intelligencer.ca · 9 Oct 2026Comparing Profound Medical (NASDAQ:PROF) & Sanara MedTech (NASDAQ:SMTI)PROF · tickerreport.com · 8 Oct 2026
0 headlines in the last 90 days name Arun Swarup Menawat; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.